MX2022010410A - Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. - Google Patents
Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.Info
- Publication number
- MX2022010410A MX2022010410A MX2022010410A MX2022010410A MX2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A MX 2022010410 A MX2022010410 A MX 2022010410A
- Authority
- MX
- Mexico
- Prior art keywords
- solid
- surfactant
- polymeric carrier
- compound
- hot melt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Extrusion Moulding Of Plastics Or The Like (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980700P | 2020-02-24 | 2020-02-24 | |
| US202063053565P | 2020-07-17 | 2020-07-17 | |
| PCT/US2021/019181 WO2021173523A1 (en) | 2020-02-24 | 2021-02-23 | Hot melt extruded solid dispersions containing a bcl2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010410A true MX2022010410A (es) | 2022-12-07 |
Family
ID=74875347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010410A MX2022010410A (es) | 2020-02-24 | 2021-02-23 | Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230295183A1 (https=) |
| EP (1) | EP4110298A1 (https=) |
| JP (1) | JP7849296B2 (https=) |
| KR (1) | KR20220158725A (https=) |
| CN (1) | CN115484933B (https=) |
| AU (1) | AU2021228622A1 (https=) |
| CA (1) | CA3173041A1 (https=) |
| IL (1) | IL295803A (https=) |
| MX (1) | MX2022010410A (https=) |
| WO (1) | WO2021173523A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4442685A4 (en) | 2021-12-06 | 2025-11-19 | Hangzhou Healzen Therapeutics Co Ltd | BCL-2 PROTEIN ANTI-APOPTOTIC INHIBITOR: PHARMACEUTICAL COMPOSITION AND USES |
| US11964990B2 (en) | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
| CN115894495B (zh) * | 2022-11-29 | 2024-08-09 | 大连理工大学 | 一种基于尿酸与苯硼酸衍生物复合晶体的纯有机室温磷光材料的制备方法 |
| CN116236583A (zh) * | 2023-03-30 | 2023-06-09 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
| CN116270660A (zh) * | 2023-03-30 | 2023-06-23 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| EP2231159A1 (en) | 2007-11-16 | 2010-09-29 | Abbott Laboratories | Method of treating arthritis |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| CN106232144B (zh) * | 2014-03-18 | 2019-12-06 | 武田药品工业株式会社 | 固体分散体 |
| WO2017132474A1 (en) * | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| EP3333167A1 (en) * | 2016-12-09 | 2018-06-13 | LEK Pharmaceuticals d.d. | Solid forms of venetoclax |
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| US12220419B2 (en) * | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
-
2021
- 2021-02-23 KR KR1020227033262A patent/KR20220158725A/ko active Pending
- 2021-02-23 IL IL295803A patent/IL295803A/en unknown
- 2021-02-23 CA CA3173041A patent/CA3173041A1/en active Pending
- 2021-02-23 JP JP2022550891A patent/JP7849296B2/ja active Active
- 2021-02-23 AU AU2021228622A patent/AU2021228622A1/en active Pending
- 2021-02-23 WO PCT/US2021/019181 patent/WO2021173523A1/en not_active Ceased
- 2021-02-23 EP EP21712350.4A patent/EP4110298A1/en active Pending
- 2021-02-23 CN CN202180016511.0A patent/CN115484933B/zh active Active
- 2021-02-23 MX MX2022010410A patent/MX2022010410A/es unknown
- 2021-02-23 US US17/798,904 patent/US20230295183A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023514750A (ja) | 2023-04-07 |
| WO2021173523A1 (en) | 2021-09-02 |
| CN115484933B (zh) | 2026-03-31 |
| EP4110298A1 (en) | 2023-01-04 |
| JP7849296B2 (ja) | 2026-04-21 |
| AU2021228622A1 (en) | 2022-10-13 |
| IL295803A (en) | 2022-10-01 |
| CA3173041A1 (en) | 2021-09-02 |
| KR20220158725A (ko) | 2022-12-01 |
| CN115484933A (zh) | 2022-12-16 |
| US20230295183A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010410A (es) | Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. | |
| EP4218731A3 (en) | Melt-extruded solid dispersions containing an apoptosis-inducing agent | |
| Napolitani et al. | Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells | |
| Galli et al. | Mast cells as sentinels of innate immunity | |
| Leite-de-Moraes et al. | Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes | |
| Zhan et al. | Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury | |
| Hershko et al. | Mast cell and T cell communication; amplification and control of adaptive immunity | |
| JP2019073550A (ja) | 炎症の治療のための免疫修飾粒子 | |
| MX349533B (es) | Dispersiones solidas que contienen un agente inductor de apoptosis. | |
| JP2010500411A5 (https=) | ||
| Terada et al. | Changes in the expression of avian β-defensins (AvBDs) and proinflammatory cytokines and localization of AvBD2 in the intestine of broiler embryos and chicks during growth | |
| JP7086077B2 (ja) | 局所領域的腫瘍治療後の免疫調節 | |
| Moss et al. | Identification of phagocytic cells, NK-like cytotoxic cell activity and the production of cellular exudates in the coelomic cavity of adult zebrafish | |
| KR102388870B1 (ko) | 가소제로서의 아미노 당의 용도 | |
| Male | Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia | |
| US20160113966A1 (en) | Composition and methods of culture supernatant of khyg-1 cells | |
| CN102688197A (zh) | 一种氟苯尼考水溶颗粒及其制备方法 | |
| HU206180B (en) | Process for producing pharmaceutical compositions with long effect and comprising macrolide | |
| Griggs et al. | Treatment of refractory undifferentiated acute myelogenous leukemia with all‐trans‐retinoic acid | |
| Dobrovolskienė et al. | Immunomodulatory properties of bacteriophage derived dsRNA of different size and their use as anticancer vaccine adjuvants | |
| Salami et al. | The effect of equine bone marrow‐derived mesenchymal stem cells on the expression of apoptotic genes in neutrophils | |
| CN105733153A (zh) | 一种免喷涂pmma材料、免喷涂pmma与abs共挤饰条及其所用冰箱 | |
| Bhowmik et al. | Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies | |
| WO2019028938A1 (zh) | 用于尿道或肛门的丁香酚/丁香油栓剂及其制备方法 | |
| Batra | Bipartite task of immunity in cancer Progression |